Dr. Mark Smith on Developing Drugs and Taking Them Through Ind Approval Process in Clinical Research

Developing an IND is very risky for pharmaceutical companies because for every product that gets approved, there many more fail. CNS studies have been greatly affected by the large number of medications that did not get approval during the past few years. Because of this, sites that specialize in CNS studies should focus on orphan diseases for potential business opportunities.